JP2018522891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522891A5 JP2018522891A5 JP2018503215A JP2018503215A JP2018522891A5 JP 2018522891 A5 JP2018522891 A5 JP 2018522891A5 JP 2018503215 A JP2018503215 A JP 2018503215A JP 2018503215 A JP2018503215 A JP 2018503215A JP 2018522891 A5 JP2018522891 A5 JP 2018522891A5
- Authority
- JP
- Japan
- Prior art keywords
- brain injury
- traumatic brain
- pharmaceutical composition
- peptides
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 19
- 230000009529 traumatic brain injury Effects 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 8
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims 6
- 208000029028 brain injury Diseases 0.000 claims 6
- 210000004556 brain Anatomy 0.000 claims 4
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 108010060215 Apolipoprotein E3 Proteins 0.000 claims 2
- 102000008128 Apolipoprotein E3 Human genes 0.000 claims 2
- 208000007333 Brain Concussion Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 108010071619 Apolipoproteins Proteins 0.000 claims 1
- 102000007592 Apolipoproteins Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022079211A JP2022113682A (ja) | 2015-07-21 | 2022-05-13 | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195183P | 2015-07-21 | 2015-07-21 | |
| US62/195,183 | 2015-07-21 | ||
| US201662288813P | 2016-01-29 | 2016-01-29 | |
| US62/288,813 | 2016-01-29 | ||
| PCT/IB2016/054318 WO2017013599A1 (en) | 2015-07-21 | 2016-07-20 | Method for treatment of traumatic brain injury targeting aggregated peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022079211A Division JP2022113682A (ja) | 2015-07-21 | 2022-05-13 | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522891A JP2018522891A (ja) | 2018-08-16 |
| JP2018522891A5 true JP2018522891A5 (cg-RX-API-DMAC7.html) | 2019-08-15 |
Family
ID=56550266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503215A Pending JP2018522891A (ja) | 2015-07-21 | 2016-07-20 | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
| JP2022079211A Pending JP2022113682A (ja) | 2015-07-21 | 2022-05-13 | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022079211A Pending JP2022113682A (ja) | 2015-07-21 | 2022-05-13 | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11327080B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3325506A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2018522891A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107849125A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016295650A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2991856A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017013599A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24446B1 (es) | 2013-03-13 | 2019-10-04 | Prothena Biosciences Ltd | Un anticuerpo monoclonal humanizado que se une a tau |
| ES2933491T3 (es) | 2016-05-02 | 2023-02-09 | Prothena Biosciences Ltd | Inmunoterapia tau |
| US10889638B2 (en) | 2016-05-02 | 2021-01-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
| US11958896B2 (en) | 2017-05-02 | 2024-04-16 | Prothena Biosciences Limited | Antibodies recognizing tau |
| PE20212324A1 (es) | 2019-03-03 | 2021-12-14 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02008145A (es) * | 2000-02-24 | 2004-04-05 | Univ Washington | Anticuerpos humanizados que secuestran al peptido beta amiloide. |
| JP5362164B2 (ja) | 2000-07-07 | 2013-12-11 | バイオアークティック ニューロサイエンス アーベー | アルツハイマー病の予防及び治療 |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| US8025878B2 (en) * | 2006-03-23 | 2011-09-27 | Bioarctic Neuroscience Ab | Protofibril selective antibodies and the use thereof |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| WO2011001366A1 (en) | 2009-06-29 | 2011-01-06 | Bioartic Neuroscience Ab | N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
| US10266585B2 (en) * | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| US8778343B2 (en) * | 2009-08-28 | 2014-07-15 | The Board Of Regents Of The University Of Texas System | Antibodies that bind tau oligomers |
| NO2539366T3 (cg-RX-API-DMAC7.html) | 2010-02-26 | 2018-04-07 | ||
| WO2012064836A1 (en) | 2010-11-10 | 2012-05-18 | Genentech, Inc. | Methods and compositions for neural disease immunotherapy |
| WO2013168174A1 (en) | 2012-05-08 | 2013-11-14 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| HK1215673A1 (zh) * | 2012-12-07 | 2016-09-09 | Biogen International Neuroscience Gmbh | 一個使用抗ab抗體減少腦部澱粉蛋白質斑的方法 |
| US20160355573A1 (en) * | 2013-09-05 | 2016-12-08 | Cornell University | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions |
| US20150126390A1 (en) * | 2013-09-12 | 2015-05-07 | Washington University | Multiplex avidity profiling of protein aggregates |
| CN112390881B (zh) | 2014-07-10 | 2025-02-21 | 生命北极神经科学公司 | 改进的Aβ初原纤维结合抗体 |
-
2016
- 2016-07-20 WO PCT/IB2016/054318 patent/WO2017013599A1/en not_active Ceased
- 2016-07-20 JP JP2018503215A patent/JP2018522891A/ja active Pending
- 2016-07-20 AU AU2016295650A patent/AU2016295650A1/en not_active Abandoned
- 2016-07-20 US US15/746,283 patent/US11327080B2/en active Active
- 2016-07-20 EP EP16742413.4A patent/EP3325506A1/en not_active Ceased
- 2016-07-20 CN CN201680042690.4A patent/CN107849125A/zh active Pending
- 2016-07-20 CA CA2991856A patent/CA2991856A1/en not_active Abandoned
-
2022
- 2022-05-13 JP JP2022079211A patent/JP2022113682A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522891A5 (cg-RX-API-DMAC7.html) | ||
| Baron et al. | The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy | |
| Jin et al. | Minocycline improves postoperative cognitive impairment in aged mice by inhibiting astrocytic activation | |
| JP2014530226A5 (cg-RX-API-DMAC7.html) | ||
| BR112016020919A2 (pt) | redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc | |
| JP2017149726A5 (cg-RX-API-DMAC7.html) | ||
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| Schmitt et al. | Role of HDACs in optic nerve damage-induced nuclear atrophy of retinal ganglion cells | |
| HK1222297A1 (zh) | 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 | |
| JP2014518275A5 (cg-RX-API-DMAC7.html) | ||
| Lee et al. | Effect of a selective mas receptor agonist in cerebral ischemia in vitro and in vivo | |
| JP2016539125A5 (cg-RX-API-DMAC7.html) | ||
| Alme et al. | Fingolimod does not enhance cerebellar remyelination in the cuprizone model | |
| JP2016507547A5 (cg-RX-API-DMAC7.html) | ||
| RU2010142456A (ru) | Синергические комбинации 5'-метилтиоаденозина | |
| Makino et al. | Enhancement of immobility in mouse forced swimming test by treatment with human interferon | |
| Liu et al. | Effects of autophagy on synaptic-plasticity-related protein expression in the hippocampus CA1 of a rat model of vascular dementia | |
| JP2019528285A5 (cg-RX-API-DMAC7.html) | ||
| ATE482711T1 (de) | Kombinationsprodukt mit einem antagonisten oder inversen agonisten von histamine-rezeptor h3 und einem antipsychotischen oder antidepressiven mittel, und ihre verwendung zur herstellung eines medikaments zur verhinderung der nachteiligen wirkungen von psychotropika | |
| EP3362096A4 (en) | OPHTHALMIC TREATMENT COMPOSITION AND CARRIER FOR THE RELEASE OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTICS | |
| Johnson‐Ansah et al. | Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia | |
| JP2016527312A5 (ja) | ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物 | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| BRPI1008103A2 (pt) | " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos " |